Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-methoxypsoralen + UVA
- Development stage
- Unknown
- Lead developer
- Madrilenian Group of Cutaneous Lymphomas
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
8-MOP + UVA, commonly known as PUVA (psoralen plus ultraviolet A) photochemotherapy, is a treatment regimen combining the photosensitizing agent 8-methoxypsoralen (methoxsalen) with long-wave ultraviolet A radiation. 8-MOP is a small molecule that intercalates into the DNA of cells; upon exposure to UVA light, it becomes chemically active and forms covalent cross-links between DNA strands. This process inhibits DNA synthesis and cell division, particularly in rapidly proliferating malignant T-cells, and induces apoptosis. The Madrilenian Group of Cutaneous Lymphomas has investigated this regimen, specifically comparing PUVA monotherapy to PUVA combined with interferon alpha-2a, as a first-line skin-directed treatment for early-stage mycosis fungoides (stages Ia, Ib, and IIa).
- Brand names
- Oxsoralen-UltraOxsoralen
- Other names
- 8-MOP + UVAmethoxsalen + UVApsoralen plus ultraviolet APUVA photochemotherapy8-methoxypsoralen
02
Targets
DNA pyrimidine bases at 5′-TpA sites
Beyond the preview
Go deeper on 8-methoxypsoralen + UVA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 8-methoxypsoralen + UVA.